CoChat

Should Benzodiazepines Be Replaced by Antidepressants in the Treatment of Anxiety Disorders? Fact or Fiction?

Open access
Rickels, Karl · 2013 · Psychotherapy and Psychosomatics
Cited by 25

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

In this issue of Psychotherapy and Psychosomatics, Offidani et al. [1] address the important clinical question of the role of benzodiazepines (BZs) in the treatment of anxiety disorders and whether there exists evidence in the literature that the BZs should be replaced by the newer antidepressants (ADs).Experts today recommend the use of newer ADs as first-line treatments for anxiety disorders [2], replacing the BZs; yet what is the evidence for this recommendation? Prescribing patterns in US outpatients for mood and anxiety disorders in the year 2007 do not seem to support this recommendation [3]. For example, 136 million prescriptions were written for ADs and 85 million for BZs and the 10 most frequently prescribed medications for either an anxiety or depression diagnosis include 7 ADs and 3 BZs, alprazolam, lorazepam and diazepam (clonazepam was not included in this survey as its use was coded under ‘convulsive disorders'). This 2007 prescribing pattern is very similar to the one reported by Stahl [4 ]for 2001.Controlled studies of BZs and ADs in anxiety disorders have been few and far apart as has been pointed out by Offidani et al. [1]. In fact, no evidence for the superiority of the newer ADs over BZs, both in terms of efficacy or safety, exists for either short-term or long-term treatment. BZ toxicity, adverse events, and withdrawal symptoms, not better efficacy, are usually cited in support of the use of ADs over BZs in anxiety disorders. Yet ADs are not better tolerated than BZs and they also cause withdrawal symptoms [5,6]. Therefore, gradual, not abrupt, taper is indicated after treatment with BZs and ADs [7,8], and a distinction between withdrawal symptoms and a return of anxiety, often a most difficult task, is critical for clinical management.A well-conducted comparison trial of a BZ and a newer AD simply does not exist, neither for acute nor chronic treatment. In fact, when in the late 1970s the National Institute of Mental Health (NIMH) made the decision to withdraw largely from supporting clinical trials of new drugs, turning new drug development over to industry, many clinically important trials, such as a comparison of BZs versus selective serotonin reuptake inhibitor ADs in anxiety disorders for example, were simply not done. It is therefore time that such comparison trials are conducted if possible under other sponsorship than that of the industry.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000353502

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 3

  1. 10.1177%2F0269881105059253 · DOI · Paper page
  2. 10.4088%2FJCP.v64n0305 · DOI · Paper page
  3. 10.1097%2FJCP.0b013e31817efbac · DOI · Paper page

Cited by

See all 25

Metadata

Authors
Rickels, K.
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2013
Volume
82
Issue
6
Pages
351-352
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W2063190694
Cited by
25
References
2
FWCI
5.25
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Should Benzodiazepines Be Replaced by Antidepressants in the Treatment of Anxiety Disorders? Fact or Fiction? https://app.cochat.ai/papers/10.1159/000353502
The paper
Rickels, K. (2013). Should Benzodiazepines Be Replaced by Antidepressants in the Treatment of Anxiety Disorders? Fact or Fiction? Psychotherapy and Psychosomatics. https://doi.org/10.1159/000353502

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.